TAKHZYRO
Clinical safety rating
cautionComprehensive clinical and safety monograph for TAKHZYRO (TAKHZYRO).
Comprehensive clinical and safety monograph for TAKHZYRO (TAKHZYRO).
Prophylaxis of hereditary angioedema (HAE) attacks in adult and pediatric patients aged 2 years and older
Lanadelumab is a fully human monoclonal antibody that binds to and inhibits the activity of plasma kallikrein, thereby preventing the cleavage of high-molecular-weight kininogen (HMWK) to bradykinin. This reduces bradykinin-mediated angioedema formation in hereditary angioedema (HAE).
| Metabolism | Lanadelumab is degraded into small peptides and amino acids via general protein catabolic pathways; no specific metabolic enzymes are involved. |
| Excretion | Primarily eliminated via proteolytic degradation; renal excretion of intact drug is negligible. <1% excreted unchanged in urine. |
| Half-life | Terminal half-life is approximately 11-19 days (mean ~14 days) in patients with hereditary angioedema, supporting every-4-week dosing. |
| Protein binding | High, approximately 97-99% bound to plasma proteins, primarily to albumin. |
| Volume of Distribution | Approximately 6-10 L (0.08-0.14 L/kg based on 70 kg), indicating limited extravascular distribution consistent with a monoclonal antibody. |
| Bioavailability | Subcutaneous: Approximately 62% (range 50-80%) after SC injection into the abdomen, thigh, or arm. |
| Onset of Action | Subcutaneous: Median time to first attack reduction is approximately 2 weeks (range 1-3 weeks) after initial dose. |
| Duration of Action | Duration of effect lasts for the dosing interval (4 weeks) with sustained attack rate reduction over long-term treatment. Attack reduction persists for at least 70 days after last dose due to long half-life. |
| Molecular Weight | 147000 |
300 mg subcutaneously every 2 weeks
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C). |
| Pediatric use | Not approved for pediatric use; safety and efficacy not established. |
| Geriatric use | No specific dose adjustment; clinical studies included limited patients aged 65 and older, but no overall differences in safety or efficacy observed. |
| 1st trimester | Limited human data; animal studies suggest low risk. Use only if clearly needed. |
| 2nd trimester | Limited data; potential risk of fetal bradycardia with C1 inhibitor deficiency treatment. Monitor. |
| 3rd trimester | Limited data; consider risk-benefit due to potential for antibody transfer and bradykinin-mediated effects. |
Clinical note
Comprehensive clinical and safety monograph for TAKHZYRO (TAKHZYRO).
| Placental transfer | IgG monoclonal antibodies actively transported across placenta, especially in second and third trimesters. Expected to cross. |
| Breastfeeding | Unknown if distributed into human milk. Due to high molecular weight, likely minimal excretion. Caution advised. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | TAKHZYRO (lanadelumab) is a monoclonal antibody. Immunoglobulin G (IgG) is known to cross the placental barrier. No adequate human data exist; animal studies showed no adverse developmental effects. Theoretical risk of fetal monoclonal antibody exposure during second and third trimesters cannot be excluded. |
| Fetal Monitoring | Standard prenatal monitoring; no specific additional monitoring required. Monitor for maternal adverse effects per standard prescribing information. |
| Fertility Effects | No human data on fertility. Animal studies (monkeys) showed no impairment of male or female fertility at doses up to 30 mg/kg. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to active substance or any excipients
| Precautions | Hypersensitivity reactions including anaphylaxis have been reported; discontinue if severe hypersensitivity occurs., Monitor for signs and symptoms of hypersensitivity reactions and initiate appropriate treatment., Increased risk of thrombotic events (based on animal studies) - use with caution in patients with known cardiovascular risk factors., May cause fetal harm based on animal reproduction studies; advise females of reproductive potential to use effective contraception. |
| Food/Dietary | No known food interactions; no dietary restrictions required. |
| Clinical Pearls | TAKHZYRO (lanadelumab) is a monoclonal antibody that inhibits plasma kallikrein, used for prophylaxis of hereditary angioedema (HAE). It is not for acute attacks. Subcutaneous administration site reactions are common; rotate injection sites. Monitor for hypersensitivity reactions. Efficacy may not be fully established until after several doses. Contraindicated in patients with known hypersensitivity to lanadelumab or any excipients. |
| Patient Advice | TAKHZYRO is a preventive treatment, not for acute HAE attacks. · You or a caregiver should be trained on proper subcutaneous injection technique. · Inject exactly as prescribed, typically every 2 weeks. · Store the medication in the refrigerator, but it can be kept at room temperature for up to 14 days once removed. · Report any signs of allergic reaction (rash, hives, itching, difficulty breathing) immediately. · You may experience pain, redness, or swelling at the injection site; these are common and usually mild. · Do not stop or change the dose without consulting your doctor. · Use contraception if of childbearing potential; discuss pregnancy planning. |
Loading safety data…